Sign up
Pharma Capital

Genprex Inc retains pharmaceutical branding company to commercialize its lung cancer drug

the firm Addison Whitney will oversee the drug's naming process, which requires regulatory approval
Oncoprex name tag
The clinical-stage gene therapy company has developed a non-small cell lung cancer treatment, currently called Oncoprex

Genprex Inc (NASDAQ:GNPX) has moved one step closer to commercializing its flagship drug candidate Oncoprex by retaining pharmaceutical branding agency Addison Whitney.

The clinical-stage gene therapy company has developed the drug to treat non-small cell lung cancer treatment.

Addison Whitney will oversee the official naming process, which requires regulatory approval.

READ: Genprex reports positive preclinical data on its drug to treat lung cancer

"Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Chairman and CEO Rodney Varner said. "Obtaining regulatory approval of proprietary and non-proprietary drug names is a necessary step in securing marketing approval, and Addison Whitney has an impressive track record in obtaining such name approvals.”

The Austin-based company’s drug fights non-small cell lung cancer by transporting cancer-fighting genes to cancerous cells.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Why Invest In Genprex, Inc.? Read More Here

Register here to be notified of future GNPX Company articles
View full GNPX profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.